Table 3. Distribution of the data according to the CAPRA scores.
| Classifications | Variables | Level (point) | No. (%) |
|---|---|---|---|
| CAPRA score | PSA at diagnosis, ng/mL | 2.0–6.0 (0) | 58 (28.6) |
| 6.1–10.0 (1) | 66 (32.5) | ||
| 10.1–20.0 (2) | 79 (38.9) | ||
| 20.1–30.0 (3) | 0 (0) | ||
| > 30 (4) | 0 (0) | ||
| Biopsy Gleason score | 1–3/1–3 (0) | 61 (30.0) | |
| 1–3/4–5 (1) | 77 (37.9) | ||
| 4–5/1–5 (3) | 65 (32.0) | ||
| Clinical T stage | T1/T2 (0) | 203 (100) | |
| T3a (1) | 0 (0) | ||
| Percent positive biopsies, % | < 34 (0) | 150 (73.9) | |
| ≥ 34 (1) | 53 (26.1) | ||
| Age at diagnosis, yr | < 50 (0) | 3 (1.5) | |
| ≥ 50 (1) | 200 (98.5) | ||
| Summed CAPRA scores | 1 | 4 (2.0) | |
| 2 | 36 (17.7) | ||
| 3 | 69 (34.0) | ||
| 4 | 39 (19.2) | ||
| 5 | 30 (14.8) | ||
| 6 | 23 (11.3) | ||
| 7 | 2 (1.0) |
CAPRA = Cancer of the Prostate Risk Assessment, PSA = prostate-specific antigen.